Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 13.2% – Here’s What Happened

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price rose 13.2% during trading on Thursday . The company traded as high as $0.37 and last traded at $0.36. Approximately 85,764,556 shares changed hands during trading, an increase of 13% from the average daily volume of 76,209,492 shares. The stock had previously closed at $0.32.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Saturday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Price Performance

The stock has a 50 day moving average of $0.28 and a two-hundred day moving average of $0.28. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The stock has a market cap of $71.60 million, a PE ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.